Melanoma researchers shine at the State's premier cancer awards ceremony

Melanoma researchers shine at the State's premier cancer awards ceremony

3 November 2017

Melanoma Institute Australia’s world-leading researchers have excelled at the 2017 Cancer Institute NSW’s Premier Awards for Outstanding Cancer Research.

Hosted by the Cancer Institute NSW, the Awards honour the achievements of individuals and teams working across the cancer research sector to lessen the impact of cancer on the people of NSW.

Leading researchers from MIA have been acknowledged with three prestigious awards for their excellence in melanoma research which is changing clinical practice and saving lives.  

MIA’s Conjoint Medical Directors, Professor Richard Scolyer and Professor Georgina Long, and their research team received the award for Excellence in Translational Cancer Research. The award recognises contributions having a lasting impact and demonstrating sustained progress against cancer.

The team has made key discoveries and transformed global melanoma patient care. Their discoveries range from defining new determinants of risk in primary melanoma which have impacted international reporting guidelines; development of diagnostic tests that have become clinical practice worldwide; identifying novel molecular phenotypes of melanoma; and leading development of novel treatments particularly in patients with advanced melanoma where there were no effective therapies previously.

Professor Richard Kefford AM has been named Outstanding Cancer Researcher of the Year. This prestigious award is given to an individual who has made an outstanding and sustained contribution to cancer research and has a record of substantive and noteworthy publications.

Professor Kefford’s research has played a seminal role in revealing the genetics of melanoma and he has authored more than 300 journal publications, chapters and books. He has been a Principal Investigator on more than 40 clinical trials exploring new immunotherapies that are transforming the treatment of melanoma. In addition, he has mentored a new generation of leading laboratory and clinical researchers in the field of cancer.

Professor Helen Rizos and the Melanoma Translational Research Team have won the Wildfire Highly Cited Publication Award. The award is given to researchers for a highly cited publication that is expected to significantly influence cancer control or further research. The publication that won Professor Rizos and the MIA team the award was published in Clinical Cancer Research and determined that first line combination therapies that target multiple pathways may have more success than an adaptive sequential approach. This publication has led to a new standard of care for patients with BRAF-mutant advanced melanoma being treated with combination BRAF and MEK inhibitors.

“We are extremely proud of our award winners but also our wide network of MIA-affiliated research teams,” said MIA’s CEO Carole Renouf. “The goal we all share is zero deaths from melanoma and we are making rapid progress towards cure.”

MIA’s Conjoint Medical Director Professor Richard Scolyer said, “The depth and breadth of research undertaken at MIA ensures that we are key players on the world stage of melanoma research. It is an honour to lead this organisation and I am delighted that our people are being recognised for their tremendous efforts.”

MIA’s Conjoint Medical Director Professor Georgina Long added, “The passionate people at MIA work tirelessly to consistently produce research that has a direct positive impact on the lives of patients and their families.”

Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow said, “Ten years ago, people diagnosed with advanced melanoma had their life expectancy measured in months. Now, Australian people with melanoma have a range of increasingly personalised treatment options. This has seen response rates improve from less than 10 per cent with older chemotherapy to between 40 and 70 per cent today.

“I commend these researchers for their tireless efforts and congratulate them on their tremendous success in changing the way we treat these cancers.”

The awards ceremony was held on Friday 3rd November at the Four Seasons Hotel Sydney. Adam Spencer, as the Master of Ceremonies, joined more than 300 pre-eminent guests from the health and medical research sector to share successes and forge collaborations.

City2Surf 2020
11 Sep 2020

City2Surf 2020

Join in the fun of the virtual event, and together we can run over melanoma!

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts from MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Melanoma Supportive Care Needs research study. 
03 Sep 2020

Melanoma Supportive Care Needs research study. 

Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New online melanoma risk calculators critical to saving lives
28 Aug 2020

New online melanoma risk calculators critical to saving lives

Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Tags: melanoma
Professor Richard Scolyer receives University of Sydney Alumni Award.
24 Aug 2020

Professor Richard Scolyer receives University of Sydney Alumni Award.

MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Tags: melanoma
Uniting together despite the distance
21 Aug 2020

Uniting together despite the distance

More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Tags: melanoma
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
03 Aug 2020

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.

For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Tags: melanoma
Important Update: Masks required at Poche Centre
24 Jul 2020

Important Update: Masks required at Poche Centre

As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask. 

Tags: melanoma
A Critical Nexus:The Clinician and the Researcher.
14 Jul 2020

A Critical Nexus:The Clinician and the Researcher.

In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.    

Tags: melanoma
New online calculator launched to determine risk of spread of melanoma
15 Jun 2020

New online calculator launched to determine risk of spread of melanoma

Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.

Tags: melanoma
Queen's Birthday Honour for Professor Georgina Long
08 Jun 2020

Queen's Birthday Honour for Professor Georgina Long

Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for  distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies. 

Tags: melanoma
Danny's inspiring survival story
30 May 2020

Danny's inspiring survival story

“I had a complete response within about six months. All of my tumours disappeared."

Tags: melanoma
MIA in the spotlight at ASCO virtual conference
30 May 2020

MIA in the spotlight at ASCO virtual conference

‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'

Tags: melanoma
Professor Richard Scolyer achieves h-index of 100
26 May 2020

Professor Richard Scolyer achieves h-index of 100

MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.

How we connected at Melanoma March Virtual 2020
21 Apr 2020

See how we connected at Melanoma March Virtual 2020

We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.

Melanoma meets its match.
07 Apr 2020

Melanoma meets its match.

A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.  

 

Next Steps for National Screening Program for Melanoma
23 Mar 2020

Next Steps for National Screening Program for Melanoma

On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.

Melanoma March Update
13 Mar 2020

Melanoma March Update

Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.   

Saving lives this summer: 'Game On Mole!'
11 Mar 2020

Saving lives this summer: 'Game On Mole!'

Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.